Seagen's stock plunges after revealing a disappointing outlook for one of its core cancer drugs

With sales up 38% last year compared to 2020, Seagen CEO Clay Siegall used the company’s Q4 call to highlight what he called an “exceptional year” for the team. But several setbacks — including a disappointing outlook on one of its core cancer drugs — left investors shaking their heads.